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Abstract
Background: Malaria Rapid Diagnostic Tests (RDTs) are widely used for diagnosing malaria. The present retrospective 
study evaluated the CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo Test targeting the Plasmodium falciparum specific 
antigen histidine-rich protein (HRP-2) and the pan-Plasmodium antigen lactate dehydrogenase (pLDH) in a reference 
setting.
Methods: The CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo Test was evaluated on a collection of samples obtained 
in returned international travellers using microscopy corrected by PCR as the reference method. Included were P. 
falciparum (n = 320), Plasmodium vivax (n = 76), Plasmodium ovale (n = 76), Plasmodium malariae (n = 23) and 
Plasmodium negative samples (n = 95).
Results: Overall sensitivity for the detection of P. falciparum was 88.8%, increasing to 94.3% and 99.3% at parasite 
densities above 100 and 1,000/μl respectively. For P. vivax, P. ovale and P. malariae, overall sensitivities were 77.6%, 18.4% 
and 30.4% respectively. For P. vivax sensitivity reached 90.2% for parasite densities above 500/μl. Incorrect species 
identification occurred in 11/495 samples (2.2%), including 8/320 (2.5%) P. falciparum samples which generated only 
the pan-pLDH line. For P. falciparum samples, 205/284 (72.2%) HRP-2 test lines had strong or medium line intensities, 
while for all species the pan-pLDH lines were less intense, especially in the case of P. ovale. Agreement between 
observers was excellent (kappa values > 0.81 for positive and negative readings) and test results were reproducible. The 
test was easy to perform with good clearing of the background.
Conclusion: The CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo Test performed well for the detection of P. falciparum 
and P. vivax, but sensitivities for P. ovale and P. malariae were poor.
Background
With an estimated 247 million cases yearly, malaria is one
of the most prevalent infectious diseases, killing 881,000
persons annually [1]. Early diagnosis and treatment are
necessary to prevent severe malaria and death. Micros-
copy still is the reference method for diagnosis, though
expertise may be lacking in both endemic and non-
endemic settings [2]. Malaria Rapid Diagnostic Tests
(RDTs) were introduced in the nineties and have under-
gone many improvements. Initially two-band tests were
used, consisting of a control line and a P. falciparum spe-
cific test line, either histidine-rich protein-2 (HRP-2) or P.
falciparum  specific lactate dehydrogenase (Pf-pLDH).
The later developed three-band RDTs detect both a P. fal-
ciparum specific antigen and an antigen of the four Plas-
modium  species, either aldolase or pan Plasmodium-
s pec i f i c  p L D H  ( p a n -p L D H )  [ 2 ] .  B y  n o w  m o r e  t h a n  6 0
RDT brands and over 200 different products have been
developed. Of those, the WHO and Foundation for Inno-
vative New Diagnostics (FIND) evaluated 70 from 26
manufacturers [3,4]. Of these products, 39 are three-band
tests that detect and differentiate P. falciparum from non-
falciparum  species. The CareStart™ Malaria HRP-2/
pLDH (Pf/pan) Combo Test is a three-band RDT detect-
ing HRP-2 and pan-pLDH. The aim of the present study
was to evaluate its performance in reference conditions
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when challenged against a collection of stored clinical
samples comprising the four Plasmodium species.
Methods
Study design
The CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo
Test was retrospectively evaluated in a reference labora-
tory on a panel of stored blood samples obtained in inter-
national travellers suspected of malaria. The reference
method was microscopy corrected by Polymerase Chain
Reaction (PCR). The study design was in compliance with
the STARD guidelines for presentation of diagnostic
studies [5].
Patients and Materials
A panel was selected from a collection of EDTA-blood
samples stored at -70°C at the Institute of Tropical Medi-
cine (ITM), Antwerp, Belgium. Between January 1996
and May 2009 these samples were obtained in patients
suspected of malaria, including international travellers
and, to a lesser extent, natives of endemic countries
returning from visiting friends and relatives. Most of
these samples were obtained in patients attending the
outpatient clinic of the ITM, another part was sent by
other Belgian laboratories to ITM for confirmation in the
scope of the national reference laboratory. The samples
collected at ITM were aliquoted and frozen at -70°C the
day of collection. Between collection and storage, the
samples remained a maximum of 8 hours at laboratory
temperature (below 25°C). The samples submitted by
Belgian laboratories for confirmation, were sent by mail
and had been exposed to ambient temperature for the
period of shipment (generally 24 hours, with a maximum
of 48 hours). The delay and processing before storage at -
70°C had been validated and were compliant with routine
laboratory procedures. The selected panel included sam-
ples with the four malaria species at varying parasite den-
sities as well as malaria-negative samples. The samples
were classified in regions according to the United Nations
classification of geographical region and composition [6].
Reference Method
All samples were blindly analyzed by microscopy and
real-time polymerase chain reaction for diagnosis of
malaria, species identification and determination of para-
site density, as described previously [7]. A species-spe-
cific PCR was adapted from Rougemont et al as described
p r e v i o u s l y  [ 7 , 8 ] .  I n  c a s e  o f  d i s c o r d a n t  r e s u l t s  b e t w e e n
microscopy and PCR, the result of PCR was used as the
reference method.
Test platforms
The CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo
Test is a lateral flow antigen detection test in a cassette
format. It is a three-band RDT targeting HRP-2 and pan-
pLDH. The presence of a unique HRP-2 line indicates an
infection with P.  falciparum, whereas a unique pan-
pLDH line is found in infection with one or more of the
non-falciparum species. The presence of both HRP-2 and
pan-pLDH lines indicates an infection with P. falciparum
or a mixed infection with P. falciparum and one or more
of the non-falciparum species.
For the evaluation of CareStart™ Malaria HRP-2/pLDH
( P f / p a n )  C o m b o  T e s t ,  t e s t  k i t s  f r o m  f o u r  d i f f e r e n t  l o t
numbers were used for evaluation, supplied in two kit
presentations : a self-test kit containing 60 individually
wrapped packages including cassette, lancet, assay buffer,
sample pipette and instructions, and a kit designed for
laboratory use with 25 individually packed cassettes. The
test kits had been stored between 18°C and 24°C before
use. All malaria tests carried out at ITM are accredited in
accordance with the requirements of the standard NBN
EN ISO 15189:2007.
Test procedures
Tests were performed according to the instructions of the
manufacturer, except that the plastic transfer straws sup-
plied in the kit were replaced by a transfer pipette
(Finnpipette, Helsinki, Finland). Readings were carried
out at daylight assisted by a standard electric bulb by
three subsequent observers, of whom the first always was
the one performing the tests. The first observer per-
formed readings at 20 minutes (which is the reading time
recommended by the manufacturer), followed by observ-
ers 2 and 3 within an additional 10 minutes. The observ-
ers were blinded to each other's readings and to the
results of microscopy and PCR.
In case no control line appeared the test was considered
invalid and was repeated. To score line intensities we
used a scoring system of five categories as defined previ-
ously [7]: none (no line visible), faint (barely visible line),
weak (paler than the control line), medium (equal to the
control line) or strong (stronger than the control line).
The test results were based on consensus agreement,
which means that an identical result read by at least two
out of three observers was withheld. In case of no consen-
sus, the results of the first reader were considered.
To assess inter-observer agreement, results of positive
and negative readings as well as line intensities were con-
sidered. Test reproducibility was evaluated by testing 15
samples representing all species at variable parasite den-
sities on five consecutive occasions.
Statistical Analysis
Sensitivity and specificity were calculated separately for P.
falciparum  and the non-falciparum  species with 95%
confidence intervals (C.I.). The interpretation of test
results for P. falciparum and the non-falciparum species
is shown in Table 1. Samples with pure gametocytaemiaMaltha et al. Malaria Journal 2010, 9:171
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were included among the P. falciparum species. The Pear-
son Chi-square test was used to determine significance of
results, or in case of small sample size, a two-tailed
Fisher's exact test. A p-value < 0.05 was considered as sig-
nificant.
Inter-observer agreements for line intensities and posi-
tive and negative test results were expressed by kappa val-
ues for each pair of observers and by the percentage of
overall agreement between the three observers. To assess
strength of associations between line intensity readings
and parasite densities Cramer's V for categorical variables
was used [7]. To assess the potential interference of sam-
ple storage on test sensitivity, multivariate analysis (logis-
tic regression) was used for each Plasmodium  species
separately. It was hypothesized that sensitivity declined in
relation to (i) decreasing parasite densities (ii) longer
duration of storage at -70°C and (iii) that there was an
interaction between the parasite densities and the dura-
tion of storage (antigen degradation related to the
amount of antigen present at the beginning). For the mul-
tivariate analysis, parasite densities were included after
log10 transformation and declines of sensitivity were
expressed as Odds ratios. Analyses were conducted using
Stata11 (Stata Corporation, Texas, USA).
Analysis of species mismatch
In case of species mismatch (P. falciparum diagnosed as
non-falciparum, or non-falciparum diagnosed as P. falci-
parum), the sample was retested with the CareStart™
Malaria HRP-2/pLDH (Pf/pan) Combo Test and with two
other RDTs (based on HRP-2 and HRP-2/pan-pLDH).
Ease of use
The technicians who performed the tests were asked to
evaluate the kit's content and instructions for clarity, and
problems and incidents during test performance were
consequently recorded.
Ethical review
The study was approved by the Institutional Review
Board of ITM and by the Ethical Committee of Antwerp
University, Belgium.
Results
Sample collection
The samples were selected from the ITM collection,
which consists of 1,200 samples. Mixed infections were
excluded and only the first sample of each patient was
considered. For P. falciparum, which is the most fre-
quently retrieved species at ITM, a panel representing the
different parasite densities, stages (including only game-
tocytes) and geographical origin, was selected. The final
panel consisted of 590 samples including infections with
P. falciparum (n = 320), Plasmodium vivax (n = 76), Plas-
modium ovale (n = 76), Plasmodium malariae (n = 23)
and  Plasmodium  negative samples (n = 95) (Table 2).
These samples were obtained in 590 patients with a
male:female ratio of 2.16:1. The median age was 35 years
Table 1: Interpretation of test results
For P. falciparum
Test Line(s) visible Species identification by microscopy corrected by PCR
P. falciparum P. vivax, P. ovale, P. Malariae /no parasites detected
Only HRP-2 or both HRP-2 and pan-pLDH True positive Species mismatch*/false positive
No test line or only pan-pLDH False negative/species mismatch** True negative
For non-falciparum species
Test Line(s) visible Species identification by microscopy corrected by PCR
P. vivax, P. ovale or P. malariae P. falciparum /no parasites detected
Only pan-pLDH True positive Species mismatch*/false positive
No test line or only HRP-2 or both HRP-2 
and pan-pLDH
False negative/species mismatch*** True negative
* Non-falciparum species diagnosed as P. falciparum
** P. falciparum diagnosed as non-falciparum species
*** Non-falciparum species diagnosed as P. falciparum or as a mixed infection with P. falciparumMaltha et al. Malaria Journal 2010, 9:171
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(range 1 - 84 years), only 15 patients (2.5%) were children
under the age of five years. Table 3 shows the results of
the microscopic identification corrected by PCR: of the
76 P. ovale samples, seven (9.2%) had originally been diag-
nosed as P. vivax by microscopy, and four out of 76 (5.3%)
P. vivax samples had originally been diagnosed as P. ovale.
The geographical distribution of the samples used is
shown in Table 2. Samples were obtained in Africa (n =
444), Asia (n = 54), Latin America and the Caribbean (n =
12) and Oceania (n = 4). Of 76 samples no data on the
geographic origin were known and could not be
retrieved. Most (268/320, 83.8%) P. falciparum infections
had been acquired in sub-Saharan Africa.
Test characteristics
No invalid test results were observed. One cassette was
broken, and one blister contained no cassette. Table 4
shows the number of positive HRP-2 and pan-pLDH lines
for all species. Tables 5 and 6 show the test characteristics
according to parasite density. For P. falciparum, the over-
all sensitivity was 88.8%. Sensitivity was related to para-
site density: it was 69.6% at parasite densities below 100/
μl and increased to 94.3% and 99.3% at parasite densities
above 100 and 1,000/μl respectively. Nineteen out of 28
false-negative samples had a parasite density below 100/
μl (including five samples with pure gametocytaemia),
eight had parasite densities ranging from 120 - 467/μl and
the remaining sample had a parasite density of 703/μl. All
of these infections had been acquired in sub-Saharan
Africa. Eight (2.5%) P. falciparum samples only reacted
with the pan-pLDH line and consequently represented
species mismatch, as they were incorrectly diagnosed as
non-falciparum species. Parasite densities of these sam-
ples ranged from 32 - 371/μl, except for one sample with a
Table 2: Species distribution and geographical origin of the 590 samples used for evaluation of the CareStartTM Malaria 
HRP-2/pLDH (Pf/pan) Combo Test
Species identification by microscopy corrected by PCR
Geography P. falciparum P. vivax P. ovale P. malariae No parasites seen
Africa (n = 444) Eastern Africa 18 12 9 5 10
Northern Africa 1 1 1
Middle Africa 97 5 24 7 37
Southern Africa 6 1 1 1
Western Africa 145 4 27 6 25
Africa 1
Asia (n = 54) Eastern Asia 1 3
Southern Asia 4 16 1 5
South-Eastern Asia 10 10 1
Western Asia 1 1
Asia 1
Latin America
and the Caribbean (n = 12)
Caribbean 1 1
South America 6 1 3
Oceania
(n = 4)
Melanesia 1 2
Micronesia 1
No data (n = 76) 36 18 12 4 6
Total (n = 590) 320 76 76 23 95Maltha et al. Malaria Journal 2010, 9:171
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parasite density of 1,123/μl; all had been acquired in sub-
Saharan Africa (Tables 3, 4 and 6). The species mismatch
results were reproducible upon retesting with CareStart™
Malaria HRP-2/pLDH (Pf/pan) Combo Test. Additional
testing of these samples with two other RDT brands
(HRP-2 and HRP-2/pan-pLDH) scored five of them as P.
falciparum; the three other samples, obtained in travel-
lers returning from Ghana and DRC, were negative (para-
site densities were 32, 70 and 210/μl).
For the non-falciparum  species, there were 80/175
(45.7%) samples correctly identified, two samples had
both a visible HRP-2 and pan-pLDH line, a single sample
showed a unique HRP-2 line and 91 samples showed no
test line (Table 4). Species mismatch results were repro-
ducible upon retesting with the CareStart™ Malaria HRP-
2/pLDH (Pf/pan) Combo Test: upon testing with two
other RDT brands they were diagnosed as non-falci-
parum species. Overall sensitivities for P . vivax, P . ovale
and P. malariae were 77.6%, 18.4% and 30.4% respectively
(Table 6). None of the Plasmodium negative samples was
scored as positive.
Line intensity reading
Tables 7 and 8 list the line intensity readings related to
parasite density. For P. falciparum, the majority (205/284,
72.2%) of positive HRP-2 test lines was read as strong or
medium, and 27.8% (79/284) were read as weak or faint.
Pan-pLDH test lines were read as strong and medium in
129 (51.4%) and as weak or faint in 122 (48.6%) of 251
positive test lines. For the pan-pLDH line intensity in
non-falciparum  species, there was a clear difference
between the three species: the P. vivax samples generated
strong and medium line intensities in half (30/61, 49.2%)
of positive samples, whereas P. ovale uniquely showed
weak or faint lines. For P. malariae, 3 out of 7 positive
pan-pLDH lines were read as medium line intensity.
For both the HRP-2 and the pan-pLDH test lines, there
was a significant relation between line intensity and para-
site density with a substantial correlation (HRP-2: V =
0.353, p < 0.001; pan-pLDH: V = 0.590, p < 0.001), but
there was considerable overlap between categories. For P.
falciparum, faint HRP-2 lines occurred exclusively at par-
asite densities below 1,000/μl, whereas a strong HRP-2
line intensity indicated a parasite density higher than
100/μl in a vast majority of samples (128/139, 92.1%). In
addition a pan-pLDH line of strong intensity indicated in
all but four (114/117, 96.6%) P. falciparum samples a par-
asite density exceeding 1,000/μl. Of the latter four sam-
ples one had a parasite density of 930/μl and the three
other samples had pure gametocytaemia. In case of spe-
cies mismatch for both P. falciparum and non-falciparum
species, line intensity readings were faint or weak for the
discordant test lines.
Inter-observer agreement and reproducibility
For both HRP-2 and pan-pLDH lines, overall agreement
and kappa values between pairs of observers for positive
and negative readings were excellent, for line intensities
Table 3: Samples tested: results of species identification by microscopy versus PCR
Results corrected by PCR
Results of microscopy Negative P. falciparum P. vivax P. ovale P. malariae Total
Negative 95 95
P. falciparum 320 320
P. vivax 72 7 79
P. ovale 46 9 7 3
P. malariae 23 23
Total 95 320 76 76 23 590
Table 4: Test line results of the CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo Test for all samples (n = 590)
HRP-2 line positive HRP-2 line negative
Samples pan-pLDH line positive pan-pLDH line negative pan-pLDH line positive pan-pLDH line negative
P. falciparum (n = 320) 244 40 8* 28
P. vivax (n = 76) 2* - 59 15
P. ovale (n = 76) - 1* 14 61
P. malariae (n = 23) - - 7 16
Negative (n = 95) - - - 95
* Species mismatchMaltha et al. Malaria Journal 2010, 9:171
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they were good (Table 9). Most differences in line inten-
sity readings between two observers occurred within one
category of difference (218/231 (94.4%) and 288/294
(98.0%) for HRP-2 and pan-pLDH respectively).
The first observer (who read the test exactly within the
recommended reading time of 20 minutes) tended to
score weaker pan-pLDH test lines and less positive
results compared to observer 2 and 3 (Figure 1), although
the differences did not reach statistical significance. As a
result, sensitivities for non-falciparum  species were
slightly higher for observers 2 and 3 (49.1% and 48.6%)
compared to observer 1 (44.6%). On the other hand,
observer 2 and 3 scored, on different occasions, two times
a faint positive pan-pLDH test line in case of a negative
sample. For HRP-2 no such tendencies in differences
were observed.
Tables 10 and 11 list the results of reproducibility for
HRP-2 and pan-pLDH. The results for HRP-2 and pan-
pLDH lines were reproducible. For the HRP-2 lines, all
differences occurred within a single category of intensity.
In two samples this resulted in subsequent faint and neg-
ative readings. For the pan-pLDH lines, differences
occurred within one (n = 5) and two (n = 2) line intensity
categories, and two samples showed subsequent faint and
negative readings.
Effect of parasite density and duration of storage on test 
sensitivity
As suspected by the sensitivities shown in Tables 5 and 6,
the relation between parasite densities and test sensitivi-
ties was statistically significant in a multivariate model
for all four Plasmodium species (Table 12). In the same
model, an effect of storage, i.e. lower sensitivities for sam-
ples stored for long versus short periods, was noted only
for P. ovale. If only samples stored from 2001 onwards
were considered, sensitivity for P. ovale (n = 38) was
29.0% (95% C.I. 15.4% - 45.9%).
Ease of use
The CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo
T est was scored as easy to perform. The clearing of the
test strip was good, and the test lines were easy visual-
ized. The HRP-2 and pan-pLDH test lines showed slightly
different color tones (more blue) as compared to the con-
trol line. The test instructions in the package insert were
scored as clear and the use of pictures was well appreci-
ated. There were slight discordances in interpretation of
the test results between the instructions of the self-test
kits and the laboratory kits. For instance, the former
stated that only the absence of both the control line and
the test lines should be read as invalid, whereas the
instructions of the laboratory test mentioned the absence
of the control line by itself as an invalid test. In addition,
the self-test mentioned a positive HRP-2 and pan-pLDH
line as positive for P. falciparum, whereas the laboratory
test added the option of mixed infection with P. falci-
parum  as well. Finally, the unique presence of a pan-
pLDH test line should be considered as a P. vivax infec-
tion according to the instructions of the self-test kit,
whereas the laboratory test more correctly mentioned the
possibility of (mixed) infections by the three non-falci-
parum species.
Table 5: Sensitivities and specificities of CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo Test for the detection of P. 
falciparum
Results of microscopy corrected by PCR Numbers Identified as P. falciparum 
by CareStart™ Malaria 
HRP-2/pLDH (Pf/pan) 
Combo Test
% Sensitivity (95% C.I.) % Specificity (95% C.I.)
All P. falciparum samples 320 284 88.8 (84.8-92.0)
Pure gametocytaemia 17 12 70.6 (44.0-89.7)
Asexual parasite density 0-100/μl 56 39 69.6 (55.9-81.2)
Asexual parasite density 101-200/μl 35 29 82.9 (66.4-93.4)
Asexual parasite density 201-1,000/μl 79 72 91.1 (82.6-96.4)
Asexual parasite density > 1,000/μl 133 132 99.3 (95.9-100)
Asexual parasite density > 100/μl 247 233 94.3 (90.7-96.9)
All other species and no parasites seen 270 3 98.9 (96.8-99.8)
No parasites seen 95 0 100.0 (96.2-100)
P. vivax 76 2
P. ovale 76 1
P. malariae 23 0Maltha et al. Malaria Journal 2010, 9:171
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Table 6: Sensitivities and specificities of CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo Test for the detection of non-
falciparum species
Results of microscopy corrected 
by PCR
Numbers Identified as non-falciparum species
by CareStart™ Malaria HRP-2/pLDH
(Pf/pan) Combo Test
% Sensitivity 
(95% C.I.)
% Specificity 
(95% C.I.)
All non-falciparum species combined 175 80 45.7 (38.2-53.4)
P. vivax samples, total 76 59 77.6 (66.6-86.4)
Parasite density ≤ 500/μl 25 13 52.0 (31.3-72.2)
Parasite density > 500/μl 51 46 90.2 (78.6-96.7)
P. ovale samples, total 76 14 18.4 (10.5-29.0)
Parasite density ≤ 500/μl 35 1 2.9 (0.1-14.9)
Parasite density > 500/μl 41 13 31.7 (18.1-48.1)
P. malariae samples, total 23 7 30.4 (13.2-52.9)
Parasite density ≤ 500/μl 11 1 9.1 (0.2-41.3)
Parasite density > 500/μl 12 6 50.0 (21.1-78.9)
P. falciparum and negative 
samples, total
415 8 98.1 (96.2-99.2)
P. falciparum 320 8 97.5 (95.1-98.9)
No parasites seen 95 0 100.0 (96.2-100)
Table 7: Line intensity consensus reading for the CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo Test for HRP-2 according 
to parasite densities
Line intensity readings, number of samples
Results of microscopy corrected by PCR Negative Faint Weak Medium Strong Total
All P. falciparum samples 36 13 66 66 139 320
P u r e  g a m e t o c y t a e m i a 53 32 4 1 7
Asexual parasite density 0-100/μl 17 5 19 8 7 56
Asexual parasite density 101-200/μl 6 2 11 9 7 35
Asexual parasite density 201-1,000/μl 7 3 13 18 38 79
Asexual parasite density > 1,000/μl 1 20 29 83 133
Asexual parasite density > 100/μl 14 5 44 56 128 247
All other species and no parasites seen 267 2 1 270
No parasites seen 95 95
P. vivax 74 1 1 76
P. ovale 75 1 76
P. malariae 23 23Maltha et al. Malaria Journal 2010, 9:171
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Discussion
In this study, the performance of the CareStart™ Malaria
HRP-2/pLDH (Pf/pan) Combo Test was retrospectively
evaluated on a large panel (n = 590) of samples obtained
in returned travellers suspected of malaria. Overall sensi-
tivity for the detection of P. falciparum was 88.8%, reach-
ing 94.3% and 99.3% in samples with parasite densities
above 100/μl and 1,000/μl respectively. Overall sensitivi-
ties for P. vivax, P. ovale and  P. malariae were 77.6%,
18.4% and 30.4% respectively, reaching 90.2%, 31.7% and
50.0% for parasite densities above 500/μl. No positive
results occurred among the Plasmodium negative sam-
ples; species mismatches occurred in 2.2% (11/495) of
samples. Agreement between observers was good and
test results were reproducible. The test was easy to per-
form with good clearing of the background. Test line
intensities for the HRP-2 line were strong and medium in
the majority of cases, but line intensities for the pan-
pLDH lines were lower, especially in the case of P. ovale.
The evaluation of an RDT in a reference setting is a log-
ical step preceding evaluations in field trials [9], but this
retrospective approach has its limitations [7,10]. For
instance, it was not possible to explore discordant or
unexpected test results by reviewing patient files or by
testing for interferences such as the rheumatoid factor. In
addition, test conditions in the reference setting are more
Table 8: Line intensity consensus reading for the CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo Test for pan-pLDH 
according to parasite densities
Line intensity readings, number of samples
Results of microscopy corrected by PCR Negative Faint Weak Medium Strong Total
All P. falciparum samples 69 60 62 12 117 320
Pure gametocytaemia 8 2 4 3 17
Asexual parasite density 0-100/μl 36 17 3 56
Asexual parasite density 101-200/μl 13 11 10 1 35
Asexual parasite density 201-1,000/μl 11 30 34 3 1 79
Asexual parasite density > 1,000/μl 1 0 11 8 113 133
Asexual parasite density > 100/μl 25 41 55 12 114 247
All other species and no parasites seen 188 20 29 14 19 270
No parasites seen 95 95
P. vivax 15 7 24 11 19 76
P. ovale 62 11 3 76
P. malariae 16 2 2 3 23
Table 9: Overall agreement and inter-observer agreement between pairs of observers for the CareStart™ Malaria HRP-2/
pLDH (Pf/pan) Combo Test assay
Overall agreement between 
three observers (%)
Agreement between pairs of observers 
(kappa values)
Results expressed as positive and negative readings
HRP-2 98.0 0.98, 0.97, 0.97
pan-pLDH 90.3 0.87, 0.87, 0.87
Results expressed as line intensity readings
HRP-2 80.7 0.82, 0.80, 0.79
pan-pLDH 75.3 0.77, 0.77, 0.77Maltha et al. Malaria Journal 2010, 9:171
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Table 10: Reproducibility of the CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo Test: HRP-2 line intensities
Readings HRP-2 line Observer
Species and parasite density Observer 1 Observer 2 Observer 3
P. falciparum
85 asexual parasites/μl S S S S S S S S S S S S S S S
90 asexual parasites/μl M M M M M M W M M W M M M M M
180 asexual parasites/μl N N F N N N N F N N N N N N N
200 asexual parasites/μl M M M M M W M W M W W M M M M
244 asexual parasites/μl M M M M M M M M W M M M M M M
465 asexual parasites/μl M M S M M M M S M M M S S S S
720 asexual parasites/μl S M S S S M M M S S S M S S S
4,464 asexual parasites/μl M M M M M M M M M M S M M S S
1,000,000 asexual parasites/μl W W W M W W W W W F W W W W W
P. malariae
275 asexual parasites/μl N F N N N N F N N N N F N N N
1,215 asexual parasites/μl N N N N N N N N N N N N N N N
P. ovale
468 asexual parasites/μl N N N N N N N N N N N N N N N
1,100 asexual parasites/μl N N N N N N N N N N N N N N N
P. vivax
432 asexual parasites/μl N N N N N N N N N N N N N N N
846 asexual parasites/μl N N N N N N N N N N N N N N N
HRP-2 line intensity of the test performed on five consecutive moments.
Each character represents a distinct test. N = None, F = Faint, W = Weak, M = Medium, S = Strong
favourable compared to the field setting. Further, an
influence of sample storage was apparent for P. ovale,
resulting in a possible underestimation of the actual sen-
sitivity. For the other species, no such effect was noted,
and a previous prospective study showed no effect of
storage on the stability of the HRP-2 antigen [11]. Finally,
stringent criteria were used for defining test characteris-
tics: the eight P. falciparum samples that showed only a
pan-pLDH line were scored as "species mismatches", as
this result represents a major diagnostic error, i.e. the
misdiagnosis of a P. falciparum infection as a non-falci-
parum  infection. However, these results could also be
considered as a correct diagnosis of "malaria", thereby
increasing the overall sensitivity up to 91.3%.The Care-Maltha et al. Malaria Journal 2010, 9:171
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Table 11: Reproducibility of the CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo Test: pan-pLDH line intensities
Readings pan-pLDH line Observer
Sample and parasite density Observer 1 Observer 2 Observer 3
P. falciparum
85 asexual parasites/μl N N N N N N N N N N N N N N N
90 asexual parasites/μl F F F F F F F F F F N F F F F
180 asexual parasites/μl F F F F F F F F F F F F F F F
200 asexual parasites/μl W W W W W W W F W F F W W F F
244 asexual parasites/μl N N N N N N N N N N N N N N N
465 asexual parasites/μl F F W W F F F F F F F F F F W
720 asexual parasites/μl W W W W W W F W W F W W W W F
4,464 asexual parasites/μl W W W W W W W F W W W W F W W
1,000,000 asexual parasites/μl S S S S S S S S S S S S S S S
P. malariae
275 asexual parasites/μl N N N N N N N N N N N N N N N
1,215 asexual parasites/μl W W W W W F W F F F N W F F W
P. ovale
468 asexual parasites/μl N N N N N N N N N N N N N N N
1,100 asexual parasites/μl N N N N N N N N N N N N N N N
P. vivax
432 asexual parasites/μl W W W W W W W W W W W W W W W
846 asexual parasites/μl M M M M M M S W W W M M W W M
pan-pLDH line intensity of the test performed on five consecutive moments.
Each character represents a distinct test. N = None, F = Faint, W = Weak, M = Medium, S = Strong
Start™ Malaria HRP-2/pLDH (Pf/pan) Combo Test has
r e c e n t l y  b e e n  e v a l u a t e d  a s  p a r t  o f  t h e  W H O / F I N D
Malaria RDT Evaluation Program [3]. This evaluation
showed for P. falciparum and  P. vivax detection rates
(percentage of naturally infected diluted human samples
detected by the product) of respectively 97.5% and 90.0%
at parasite densities of 200/μl, and detection rates of
100.0% and 95.0% at parasite densities of 2,000-5,000/μl
[3].
The detection rates as demonstrated by WHO/FIND
are slightly higher as compared to the sensitivities found
in the present study, but the differences were not statisti-Maltha et al. Malaria Journal 2010, 9:171
http://www.malariajournal.com/content/9/1/171
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cally significant. Comparisons are difficult as the present
study included unprocessed clinical samples with a wild
range of parasite densities and the WHO/FIND evalua-
tion used series of diluted samples at fixed parasite densi-
ties (200/μl and 2,000-5,000/μl).
A similar product of the same company, the CareStart™
Pf/Pv Combo (detecting HRP-2 and P. vivax-specific
pLDH) has been evaluated in Ethiopia [12]. This study
reported higher sensitivities for P. falciparum (99.4%).
However, it included exclusively P. falciparum samples
with parasite densities above 100/μl, which is above the
detection threshold of most RDTs. In addition, small dif-
ferences may also be explained by the fact that we
included P. falciparum samples with pure gametocytae-
mia as positive samples: in the scope of travel medicine
this is a reasonable option [13], but in the present study
five out of 17 samples did not react with the HRP-2 line
and hence decreased overall sensitivity. Another product
of the same company, the CareStart™ Malaria pLDH (Pf/
pan) Combo Test has been evaluated in a field study in
Madagascar [14]. This study reported sensitivities for P.
falciparum  that are comparable to the present one,
including low values at parasite densities < 100/μl (60,0%)
and increasing sensitivity at higher parasite densities
(100% at > 500/μl). For P. vivax there were only nine sam-
ples included, making comparison difficult. The same
product (CareStart™ Malaria pLDH (Pf/pan) Combo
Test) and another product of the CareStart™ brand
(Malaria pLDH (pan)) have recently been evaluated in
Myanmar [15]. Reported sensitivities for the detection of
P. vivax were significantly higher than those found in the
present study in case of the CareStart™ Malaria pLDH
(pan) (91.0%), but for the CareStart™ Malaria pLDH (pan/
Pf) they were in line with the present findings (78.5%).
Studies evaluating other RDTs in non-endemic countries
report similar sensitivities as those found for the Care-
Start™ Malaria HRP-2/pLDH (Pf/pan) Combo Test in the
present study: for P. falciparum they ranged from 87.5-
99.0%, with one exception of 76.2% [7,10,16-21]. For P.
vivax, RDTs detecting pan-pLDH showed sensitivities of
33.5% and 62.0%-95.0%,[7,10,13,18,20,22] compared to
46.0%-93.0% [13] for those RDTs targeting aldolase. The
increase of sensitivities at higher parasite densities is a
well-known phenomenon with breakpoints around 100/
μl (P. falciparum) and 500/μl (P. vivax) [7,10,13,22,23].
Unlike the WHO/FIND evaluation, the present study
included P. ovale and P. malariae samples, for which sen-
sitivities were poor. Previous studies that included P.
ovale  or  P. malariae species reported sensitivities for
these species combined between 36 - 95% for pan-pLDH
and 7 - 80% for aldolase based RDTs [13]. In addition, a
previous study with a study design similar to the present
one reported sensitivities for P. ovale and P. malariae of
76.3% and 45.2% respectively [7]. Even taken into account
an underestimation of the sensitivity for P. ovale (due to
an effect of sample storage), the presently found low sen-
sitivities for P. ovale and P. malariae are of concern given
the name and the claimed performance of the test. In a
field study however, a related RDT of the same company,
the CareStart™ two-band RDT targeting pan-pLDH,
detected all six P. malariae infections, though parasite
densities were not given [24].
Of note, in the present study there were eight P. falci-
parum samples (2.5%) that gave a reaction only with the
pan-pLDH line but not with the HRP-2 line. Geographic
origin of samples probably did not contribute to the spe-
cies mismatch, as all eight samples were from patients on
their return from sub-Saharan Africa where HRP-2 muta-
tions have not yet been described [25]. Low parasite den-
sities close to the detection threshold may explain for the
failure of HRP-2 detection of these samples. This species
mismatch is of concern, because misdiagnosis of P. falci-
parum infection and therefore treatment with ineffective
drugs can have fatal consequences [26].
In line with studies on other RDTs [7,16,27,28], there
was a correlation between line intensities and parasite
densities, and there were, although to a lesser extent than
observed for another RDT [7], diagnostic clues to parasite
densities when scoring line intensities (such as a strong
HRP-2 line intensity indicating a parasite density > 100/
μl). The low intensities of the pan-pLDH lines, especially
for the non-falciparum species, are of concern especially
when extrapolating the present findings to field settings
in both endemic and non-endemic settings, where disre-
garding faint test lines as negative results is a common
mistake [29-33].
The agreement between observers was excellent for
positive and negative readings and good for line intensity
readings, and test reproducibility was also good. Of inter-
est is the observation that reading beyond the reading
time increased the number of positive pan-pLDH lines,
with an increase in sensitivity (although not significantly)
at the expense of a slightly lower specificity. Antigen-anti-
body reactions are time dependent, explaining for the Figure 1 Pan-pLDH line intensity readings per observer.Maltha et al. Malaria Journal 2010, 9:171
http://www.malariajournal.com/content/9/1/171
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increase in sensitivity, but on the other hand, the so-
called backflow phenomenon (non-specific binding) may
have interfered, explaining for the apparently false-posi-
tive reactions observed by one out of three readers in the
Plasmodium negative samples [34].
The CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo
Test was scored as easy to perform by the present team.
The good clearance of the background facilitated reading
of faint and weak test lines but the difference in color
tone between control and test lines hindered reading of
test line intensity. Slight improvements to the package
insert and manufacturer's instructions are to be expected,
especially with regards to interpretation of the test
results. This is of particular concern in the case of the
self-test kit, designed for travellers or expatriates, who are
among the most inexperienced end-users [19,35].
In conclusion, the present study demonstrated that the
CareStart™ Malaria HRP-2/pLDH (Pf/pan) Combo Test
performs well for the detection of P. falciparum and P.
vivax infections, but poorly for P. ovale and P. malariae.
The occasional species mismatches, in particular P. falci-
parum samples identified as non-falciparum species, are
to be explored and improvements in test instructions
should be made.
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